Company profile
Editas Medicine, Inc.
NASDAQ:EDITBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Brinretigene Vesgedparvovec | phase1_2 | — | 1 | unknown |
| Renizgamglogene Autogedtemcel | phase1_2 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04853576 | phase1_2 | active_not_recruiting | 2021-05-04 | 2025-08-01 | Editas Medicine, Inc. | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) |
| NCT05444894 | phase1_2 | active_not_recruiting | 2022-04-29 | 2025-09-01 | Editas Medicine, Inc. | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) |
| NCT03872479 | phase1_2 | unknown | 2019-09-26 | 2025-05-23 | Editas Medicine, Inc. | Single Ascending Dose Study in Participants With LCA10 |
FDA applications (0)
No records yet.